Amgen (Nasdaq: AMGN) will acquire DeCode Genetics for $415 million.

DeCode, headquartered in Reykjavik, Iceland, is a human genetics research company that focuses on the link between genomes and disease susceptibility. The company was founded in 1996 and has discovered risk factors for dozens of diseases.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.